Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.29 Million GBP | -49.3% |
| 2022 | 20.3 Million GBP | -64.92% |
| 2021 | 57.86 Million GBP | 226.17% |
| 2020 | 17.74 Million GBP | 268.3% |
| 2019 | 4.81 Million GBP | 13.69% |
| 2018 | 4.23 Million GBP | 24.25% |
| 2017 | 3.41 Million GBP | -0.93% |
| 2016 | 3.44 Million GBP | 30.68% |
| 2015 | 2.63 Million GBP | -17.58% |
| 2014 | 3.19 Million GBP | 40.3% |
| 2013 | 2.27 Million GBP | -8.51% |
| 2012 | 2.49 Million GBP | -34.66% |
| 2011 | 3.81 Million GBP | 27.5% |
| 2010 | 2.98 Million GBP | 0.61% |
| 2009 | 2.97 Million GBP | 7.76% |
| 2008 | 2.75 Million GBP | 21.29% |
| 2007 | 2.27 Million GBP | 30.11% |
| 2006 | 1.74 Million GBP | 79.18% |
| 2005 | 975 Thousand GBP | 323.91% |
| 2004 | 230 Thousand GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 5.46 Million GBP | 198086.43% |
| 2023 Q1 | 2757.00 GBP | -99.96% |
| 2023 FY | 10.2 Million GBP | -49.71% |
| 2023 Q4 | 2389.00 GBP | 0.0% |
| 2023 Q3 | 2389.00 GBP | -99.96% |
| 2022 Q1 | 7004.50 GBP | -99.96% |
| 2022 FY | 20.3 Million GBP | -64.92% |
| 2022 Q4 | 6.24 Million GBP | 198310.43% |
| 2022 Q3 | 3145.50 GBP | -99.98% |
| 2022 Q2 | 13.95 Million GBP | 199157.62% |
| 2021 Q3 | 9484.50 GBP | -99.98% |
| 2021 Q1 | 19.44 Thousand GBP | -99.84% |
| 2021 FY | 57.86 Million GBP | 226.17% |
| 2021 Q2 | 38.76 Million GBP | 199231.55% |
| 2021 Q4 | 18.9 Million GBP | 199225.21% |
| 2020 Q3 | 6332.50 GBP | -99.87% |
| 2020 Q2 | 4.94 Million GBP | 194738.46% |
| 2020 Q1 | 2538.00 GBP | -99.9% |
| 2020 Q4 | 12.53 Million GBP | 197862.89% |
| 2020 FY | 17.74 Million GBP | 268.3% |
| 2019 Q1 | 1103.00 GBP | -6.01% |
| 2019 Q3 | 1305.50 GBP | -99.94% |
| 2019 FY | 4.81 Million GBP | 13.69% |
| 2019 Q4 | 2.49 Million GBP | 191091.11% |
| 2019 Q2 | 2.15 Million GBP | 195548.23% |
| 2018 Q3 | 1173.50 GBP | 24.18% |
| 2018 Q1 | 945.00 GBP | 4.48% |
| 2018 FY | 4.23 Million GBP | 24.25% |
| 2018 Q2 | 945.00 GBP | 0.0% |
| 2018 Q4 | 1173.50 GBP | 0.0% |
| 2017 Q3 | 904.50 GBP | 12.99% |
| 2017 FY | 3.41 Million GBP | -0.93% |
| 2017 Q4 | 904.50 GBP | 0.0% |
| 2017 Q1 | 800.50 GBP | -8.83% |
| 2017 Q2 | 800.50 GBP | 0.0% |
| 2016 FY | 3.44 Million GBP | 30.68% |
| 2016 Q2 | 843.00 GBP | 0.0% |
| 2016 Q4 | 878.00 GBP | 0.0% |
| 2016 Q1 | 843.00 GBP | 7.32% |
| 2016 Q3 | 878.00 GBP | 4.15% |
| 2015 Q4 | 785.50 GBP | 0.0% |
| 2015 FY | 2.63 Million GBP | -17.58% |
| 2015 Q3 | 785.50 GBP | 47.79% |
| 2015 Q2 | 531.50 GBP | 0.0% |
| 2015 Q1 | 531.50 GBP | 27.76% |
| 2014 Q2 | 1182.00 GBP | 0.0% |
| 2014 Q1 | 1182.00 GBP | 119.7% |
| 2014 Q4 | 416.00 GBP | 0.0% |
| 2014 FY | 3.19 Million GBP | 40.3% |
| 2014 Q3 | 416.00 GBP | -64.81% |
| 2013 Q3 | 538.00 GBP | -10.48% |
| 2013 Q1 | 601.00 GBP | 0.0% |
| 2013 Q4 | 538.00 GBP | 0.0% |
| 2013 Q2 | 601.00 GBP | 0.0% |
| 2013 FY | 2.27 Million GBP | -8.51% |
| 2012 FY | 2.49 Million GBP | -34.66% |
| 2011 FY | 3.81 Million GBP | 27.5% |
| 2010 FY | 2.98 Million GBP | 0.61% |
| 2009 FY | 2.97 Million GBP | 7.76% |
| 2008 FY | 2.75 Million GBP | 21.29% |
| 2007 FY | 2.27 Million GBP | 30.11% |
| 2006 FY | 1.74 Million GBP | 79.18% |
| 2005 FY | 975 Thousand GBP | 323.91% |
| 2004 FY | 230 Thousand GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -595.992% |
| CSL Limited | 3.44 Billion USD | 99.702% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 88.141% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -109.276% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3832.357% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 65.174% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 72.375% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -585.266% |
| Mesoblast Limited | 5.9 Million USD | -74.382% |
| Marizyme, Inc. | 19.23 Million USD | 46.507% |
| Genus plc | 147.7 Million USD | 93.032% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -17.231% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -667.175% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -23.42% |
| ContraFect Corporation | 56.88 Million USD | 81.909% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -133.449% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | 72.707% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -268.842% |
| MultiCell Technologies, Inc. | 567.42 USD | -1813723.975% |
| Accustem Sciences Inc. | 3.74 Million USD | -174.716% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 88.025% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1834.725% |
| Q BioMed Inc. | 3.43 Million USD | -199.48% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 58.357% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -291.7% |
| Biomind Labs Inc. | 994.18 Thousand USD | -935.223% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -53.2% |
| Skye Bioscience, Inc. | 13.54 Million USD | 24.031% |
| SQZ Biotechnologies Company | 85.61 Million USD | 87.979% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 41268.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -104.124% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -252.921% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 35.716% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2541.914% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 95.436% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -402.366% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -460.843% |
| GB Sciences, Inc. | 1.42 Million USD | -624.529% |
| Alpha Cognition Inc. | 9.7 Million USD | -6.042% |
| argenx SE | 1.53 Billion USD | 99.329% |
| HST Global, Inc. | 140.9 Thousand USD | -7204.108% |
| Halberd Corporation | 74.84 Thousand USD | -13651.637% |
| Enzolytics Inc. | 2.17 Million USD | -372.217% |
| Resverlogix Corp. | 12.71 Million USD | 19.037% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -181.918% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 82.082% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 89.639% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -885.824% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -484.88% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -327.954% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -452.036% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -551.658% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -202.263% |
| AVAX Technologies, Inc. | 7.31 Million USD | -40.788% |
| ONE Bio Corp. | 6.44 Million USD | -59.717% |
| Zenith Capital Corp. | 8.94 Million USD | -15.084% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.753% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -58978.124% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -319.172% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5900.851% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -435.789% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -814.918% |
| Agentix Corp. | 1.37 Million USD | -650.279% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.41 Million USD | -327.034% |
| Helix BioMedix, Inc. | 1.97 Million USD | -421.898% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 5.291% |
| BioStem Technologies, Inc. | 22.97 Million USD | 55.203% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -5570.992% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -670.688% |
| LadRx Corporation | 3.81 Million USD | -170.004% |
| Cell Source, Inc. | 4.32 Million USD | -137.946% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2377.141% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1014.444% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1014.444% |
| NovAccess Global Inc. | 2.46 Million USD | -317.227% |
| Affymax, Inc. | 39.38 Million USD | 73.869% |
| Itoco Inc. | 919.14 Thousand USD | -1019.739% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -142.827% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -819.75% |
| CytoDyn Inc. | 18.05 Million USD | 43.006% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -40791.573% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -4576.524% |
| Qrons Inc. | 643.67 Thousand USD | -1498.939% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -624.895% |
| SYBLEU INC | 160.87 Thousand USD | -6297.474% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -361.55% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1450.0% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -466.64% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1755.933% |
| International Stem Cell Corporation | 5.27 Million USD | -95.257% |
| Bioxytran, Inc. | 3.82 Million USD | -169.414% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -19450.929% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -50492.341% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 71.621% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -536.094% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1298.683% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -230.826% |
| Neutra Corp. | 243.82 Thousand USD | -4121.129% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 41.044% |
| PureTech Health plc | 144.59 Million USD | 92.882% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 49.77% |
| IXICO plc | 4.7 Million USD | -118.653% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -16.994% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 91.259% |
| CSL Limited | 3.89 Billion USD | 99.736% |
| Cellectis S.A. | 97.32 Million USD | 89.425% |